➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Johnson and Johnson
Moodys
Colorcon
Boehringer Ingelheim

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DABIGATRAN ETEXILATE MESYLATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Dabigatran Etexilate Mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01976507 Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Active, not recruiting Boehringer Ingelheim Phase 4 2013-10-01 The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures.
NCT01976507 Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Active, not recruiting Vanderbilt University Phase 4 2013-10-01 The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures.
NCT02102633 Drug Interaction Study Between Bosutinib And Dabigatran Completed Pfizer Phase 1 2014-05-01 The study evaluates the effect of a single oral dose of bosutinib on the single dose pharmacokinetics of dabigatran, a p-glycoprotein substrate, in healthy subjects.
NCT02945020 A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants Recruiting Janssen Research & Development, LLC Phase 1 2016-11-01 The purpose of this study is to evaluate the effect of steady-state concentrations of odalasvir (ODV), as a single agent or in combination with simeprevir (SMV), on the single-dose pharmacokinetics of dabigatran etexilate in healthy participants.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dabigatran Etexilate Mesylate

Condition Name

Condition Name for Dabigatran Etexilate Mesylate
Intervention Trials
Healthy 3
Quizartinib 1
Acute Pancreatitis 1
Pharmacokinetics 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dabigatran Etexilate Mesylate
Intervention Trials
Atrial Fibrillation 1
Pancreatitis 1
Thromboembolism 1
Atrial Flutter 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dabigatran Etexilate Mesylate

Trials by Country

Trials by Country for Dabigatran Etexilate Mesylate
Location Trials
United States 3
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dabigatran Etexilate Mesylate
Location Trials
Arizona 1
Florida 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dabigatran Etexilate Mesylate

Clinical Trial Phase

Clinical Trial Phase for Dabigatran Etexilate Mesylate
Clinical Trial Phase Trials
Phase 4 1
Phase 1 4
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dabigatran Etexilate Mesylate
Clinical Trial Phase Trials
Active, not recruiting 2
Not yet recruiting 2
Completed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dabigatran Etexilate Mesylate

Sponsor Name

Sponsor Name for Dabigatran Etexilate Mesylate
Sponsor Trials
Boehringer Ingelheim 1
Daiichi Sankyo Co., Ltd. 1
Mayo Clinic 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dabigatran Etexilate Mesylate
Sponsor Trials
Industry 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Mallinckrodt
McKesson
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.